Lenaerts works on development of drugs to combat tuberculosis, and resistance and persistence of the lung disease that affects people around the world.
Lenaerts is involved in mycobacterial therapeutics, focused on development and application of novel preclinical animal models to further both anti-tuberculosis drug discovery and assess anti-mycobacterial resistance and latent tuberculosis.
Current research projects explore development of new in vitro assays and animal models to accelerate TB drug evaluation, as well as use of selective animal models and advanced pathology methods to study various mycobacterial populations with respect to location, pathology and drug responses.
Lenaerts holds a B.S. in biology, an M.S. in physiology and biochemistry, and a Ph.D. in molecular biology from the State University of Ghent in Belgium.